Document Type
Article
Publication Date
2-1-2022
Abstract
Cholangiocarcinoma is a highly morbid gastrointestinal malignancy for which available therapies are limited. Standard of care includes cytotoxic chemotherapies such as gemcitabine, platinum agents, nab-paclitaxel, and fluoropyrimidine analogues. However, tolerability of these regimens varies, and patients who do not tolerate chemotherapy have limited targeted therapies and immunotherapy options. In cholangiocarcinoma, mesenchymal-epithelial transition factor (MET) amplification may present an additional opportunity for a targeted therapeutic approach, especially considering emerging data in non-small cell lung cancer. In this case, we present a metastatic cholangiocarcinoma patient with high-level MET gene amplification for whom capmatinib, a tyrosine kinase inhibitor with activity against c-MET, provided a partial response after cessation of chemotherapy.
Recommended Citation
Lefler, Daniel S; Tierno, Marni Brisson; and Bashir, Babar, "Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature" (2022). Department of Medical Oncology Faculty Papers. Paper 171.
https://jdc.jefferson.edu/medoncfp/171
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
35129063
Language
English
Comments
This article is the author’s final published version in Cancer Biology and Therapy, Volume 23, Issue 1, February 2022, Pages 112 - 116.
The published version is available at https://doi.org/10.1080/15384047.2022.2029128. Copyright © Lefler, Tierno, and Bashir.